

Molekule Consulting announces Dr. Mark Powzaniuk, PhD, MBA as Head of Oncology Practice

Dr. Mark Powzaniuk will join Molekule Consulting as Head of Oncology Practice on May 27, 2019. Mark joins Molekule from Merck & Co. / MSD where he served as Head of Global Competitive Intelligence, Oncology. In this role, Mark built a world-class competitive intelligence organization focused on end-to-end strategic support of Merck Oncology from discovery to lifecycle management.

Dr. Powzaniuk has 20 years of pharmaceutical industry experience. As a seasoned pharmaceutical professional, Mark brings a unique background of science and business acumen. His experiences include strategy and competitive intelligence, finance, project management, business integration and basic biomedical research.

Dr. Powzaniuk has a deep understanding and appreciation of biopharma strategy – cross-therapeutically – and is able to organize and implement competitive intelligence strategy and processes in support of Molekule’s rich and growing client base.



David Alderman,
President of Molekule
Consulting commented:

“I am privileged and honored to announce Mark’s joining Molekule as Head of Oncology Practice. He is a seasoned and highly experienced biopharma executive with a strong track record of success. Molekule continues our growth trajectory and Mark’s joining occurs as we enter a new and exciting phase in our business evolution. Molekule’s priorities to continually deliver ethically driven, precise & accurate and actionable intelligence & strategy solutions to our client partners is paramount. With Mark leading an already strong and capable team, Molekule ensures successful execution on these key business priorities while continuing to drive sustainable growth.”



Dr. Daniel Pascheles,
CEO of Molekule
Consulting continues,

“Mark is a consummate professional with a deep understanding of oncology, the overarching issues impacting biopharma and competitive intelligence and strategy. It is a great honor to welcome Mark to the Molekule team, where I know he will make an immediate impact and facilitate Molekule’s continued expansion as we strive to be the market leader in biopharmaceutical competitive intelligence and strategy consulting. Mark will lead Molekule’s Oncology Practice – and will be a core member of the Molekule Leadership Team.”

About Molekule Consulting (“Molekule”)

Molekule Consulting (“Molekule”) is a recognized global consultancy servicing life science and biopharmaceutical clients at all stages of the product and portfolio lifecycle. The firm creates highly refined strategic outputs supporting diverse business functions including strategic planning and forecasting, marketing analytics, business development, and operations.

To accomplish this goal, the firm integrates and refines proprietary and non-proprietary research to create real-time analysis and assessments, providing leadership during key business milestones and workshops. Molekule seeks to align intelligence outcomes, focuses results, and enable our client partners the ability to “win” in a highly dynamic and competitive biopharmaceutical environment.

The firm has remained a trusted partner for top-tier biopharmaceutical companies since inception. Molekule was founded in 2012 by David Alderman, who sought to create a firm combining an ethos of strategic & actionable competitive insight with industry leading dedication to clients. As of January 2017, Dr. Daniel Pascheles was appointed to the role of CEO at Molekule Consulting.

Molekule Consulting is headquartered in



Miami, Florida, USA

Molekule’s European headquarters are located in



Zurich, Switzerland

For further information about the Company’s business and activities please visit



molekuleconsulting.com

or follow Molekule on LinkedIn



**For Further Information
Please Contact:**

David Alderman, President
Tel.: +1 305 504 3030
Email: dalderman@molekuleconsulting.com

Dr. Daniel Pascheles, CEO
Tel: + 1 973 981 0000
Email: dpascheles@molekuleconsulting.com

**For Other Inquiries
Please Contact:**

info@molekuleconsulting.com